a Background Co-trimoxazole is a sulfonamide-containing antibiotic that is effective in the treatment of several infections and for prophylaxis of Pneumocystis jiroveci pneumonia. This drug has been reported as a common culprit drug for the Stevens-Johnson syndrome (SJS) and for toxic epidermal necrolysis (TEN). Human leukocyte antigens (HLAs) play a key role in the immunopathogenesis of severe cutaneous reactions induced by several drugs. This study investigated the association between the HLA class I and HLA-DRB1 polymorphisms and co-trimoxazoleinduced SJS/TEN in a Thai population.
Introduction
Co-trimoxazole is a combination of antibiotics that consists of sulfamethoxazole and trimethoprim in the weight ratio of 5 : 1. This drug is effective for treatment of a variety of bacterial, fungal, and protozoal infections. In addition, co-trimoxazole is commonly used for the prophylaxis of Pneumocystis jiroveci pneumonia (PJP) in HIV/AIDs patients.
To date, the use of co-trimoxazole for the treatment of infections other than PJP is restricted because of the high incidence of cutaneous adverse drug reactions. Cotrimoxazole-related cutaneous adverse reactions range from mild cutaneous reactions, such as maculopapular rash, photosensitivity, or urticaria, to life-threatening severe cutaneous adverse reactions, such as druginduced hypersensitivity syndrome, Stevens-Johnson Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (www.pharmacogeneticsandgenomics.com).
syndrome (SJS), and toxic epidermal necrolysis (TEN). SJS and TEN are variants of the same disease, with a rapidly developing blistering exanthema of purpuric macules and target-like lesions with skin detachment of less than 10% of the body surface area in SJS and more than 30% of the body surface area in TEN. The mortality rate ranges between 5 and 10% in SJS and increases to 30-40% in TEN [1, 2] . Drug-induced hypersensitivity syndrome is characterized by generalized maculopapular eruptions, high fever, eosinophilia, atypical lymphocytes, and systemic manifestations, with a mortality rate of~10%.
Co-trimoxazole has been reported as the most common culprit drug for SJS/TEN in several countries. The incidence of SJS/TEN caused by co-trimoxazole has been estimated at 1-3 cases/100 000 users among Whites [2] . Moreover, the incidence of co-trimoxazole-induced SJS/TEN is higher among HIV-infected patients than in the general population [3] . According to the data from the spontaneous reports of the Health Product and Vigilance Center of Thailand from 1984 to 2010, cotrimoxazole is the most common culprit drug for SJS and TEN in Thailand, with at least 1889 patients suffering from SJS and 151 from TEN caused by co-trimoxazole over the last 20 years.
Although severe adverse cutaneous reactions (SCARs) are generally classified as unpredictable life-threatening reactions, recent studies have demonstrated that certain SCARs caused by several drugs are associated with genetic polymorphisms of human leukocyte antigens (HLAs). A strong association between HLA-B*15:02 and SJS/TEN caused by carbamazepine, and HLA-B*58:01 and SCARs caused by allopurinol have been reported in Chinese, Thai, and several other ethnic populations [4 -12] . Moreover, other cutaneous reactions, such as hypersensitivity caused by abacavir, an antiretroviral drug, are strongly associated with HLA-B*57:01, particularly in White populations [13, 14] .
The link between HLA genetic polymorphisms and SCARs induced by sulfonamide drugs was first investigated in 13 French patients, and weak associations between HLA-A*29, B*12, and DR*7 and sulfonamiderelated TEN were observed [15] . Furthermore, associations between the HLA-B*38:01 and HLA-B*38:02 alleles and sulfamethoxazole-induced SJS/TEN were observed from an investigation of 28 European patients [7] . The issue of ethnicity is well recognized for the associations between HLA alleles and SCARs induced by carbamazepine and abacavir, whether these HLA alleles are associated with the risk for co-trimoxazoleinduced SJS/TEN needs to be explored in other ethnic populations.
It is known that the HLA allele is not just a genetic marker but is also a key element in the pathogenesis of SCARs, as demonstrated by abacavir-induced hypersensitivity [16] . As co-trimoxazole is the most common culprit drug for SJS and TEN in several countries including Thailand, identification of patients who are at high risk for co-trimoxazole-induced SCARs is of clinical importance. This study was therefore conducted as a multicenter case-control study to determine the association between SJS/TEN and HLA class I and HLA-DRB1 polymorphisms. The associated HLA alleles may then be used as genetic markers for the prediction of co-trimoxazoleinduced SJS/TEN in the Thai population.
Materials and methods

Study population
Patients with co-trimoxazole-induced SJS or TEN were recruited from local hospitals in Thailand. These patients had been diagnosed with co-trimoxazole-induced SJS or TEN and were admitted to the hospital for treatment of these SCARs between 1981 and 2014. Patients hospitalized between 1981 and 2008 were identified by retrospectively reviewing medical records, whereas patients hospitalized between 2008 and 2014 were prospectively enrolled in the study. The diagnosis of cutaneous reactions was made by an internist or a dermatologist on the basis of the clinical morphology of the skin lesions of the patients. SJS and TEN were defined by widespread development of blistering exanthemas of purpuric macules and target-like lesions, accompanied by mucosal involvement and skin detachment. SJS, the overlap between SJS and TEN, and TEN were defined by skin detachments of less than 10%, 10-30%, and greater than 30% of the body surface area, respectively [17] . All cases recruited to this study were reviewed by the pharmacists who were responsible for adverse drug reaction surveillance activities in each hospital based on available photographs of skin lesions, blood chemistry data, clinical information, medical history, and medications used before and during admission to the hospital.
Both the Naranjo algorithm [18] and the algorithm for assessment of drug causality for SJS and epidermal necrolysis (ALDEN) [19] were used to determine whether co-trimoxazole was the culprit drug for SCARs. Patients with an ALDEN or Naranjo score for cotrimoxazole, but not for other concomitant drugs, in the category of probable or very probable were recruited as cases. No in-vivo or ex-vivo testing (i.e. epicutaneous patch, ELISpot) was performed as an adjunctive to clinical diagnosis. Patients who tolerated co-trimoxazole for more than 6 months without any evidence of cutaneous reactions were recruited as controls. The tolerant control patients were recruited from the same hospitals as the case group. Patients were informed both verbally and in writing about the experimental procedures and the purpose of the study. Written informed consent was obtained from each participant. The study protocol within the hospital networks of Khon Kaen University was approved by the Khon Kaen Ethics Committee for Human Research, Khon Kaen University, Thailand. The study protocol was also approved by the Institutional Review Board of each hospital, along with approval from the Institute for Development of Health Research Protection, Ministry of Public Health, Thailand.
Genomic DNA preparation A volume of 10 ml of venous blood was collected in a tube coated with EDTA. Leukocytes were separated by centrifugation at 3500 rpm for 15 min. Genomic DNA was isolated from the leukocytes using the MagNA Pure Compact Nucleic Acid Isolation Kit I (Roche Applied Science, Mannheim, Germany).
HLA genotyping HLA-A, HLA-B, HLA-C, and HLA-DRB1 alleles were genotyped using the reverse sequence-specific oligonucleotide probes method with the commercial WAKFLOW HLA-typing kit (Wakunaga Pharmaceutical Co. Ltd, Hiroshima, Japan). The results were read on the Luminex 100 system (Luminex Corporation, Austin, Texas, USA). The HLA alleles were analyzed using WAKFLOW Typing Software, version 3.2 (Wakunaga Pharmaceutical Co. Ltd).
Statistical analysis
Statistical analysis between cases and controls for the clinical characteristics were carried out using Student's ttest. The associations of HLA alleles with cotrimoxazole-induced SJS and TEN were determined by Fisher's exact test, and the strength of association was estimated by calculating the odds ratios (ORs) and 95% confidence intervals (CIs) using STATA software (Stata Corporation, College Station, Texas, USA).
As HLA regions are known regions with high levels of linkage disequilibrium (LD), Bonferroni's correction was applied, which is generally considered a conservative test for multiple testing correction in regions with high LD. Bonferroni's correction was based on the number of alleles with more than three carriers in the study populations (12 for HLA-A, 20 for HLA-B, 16 for HLA-C, and 13 for HLA-DRB1). Haplotype association analysis were carried out using 'haplo.stats' packages. The haplotypes were inferred using the expectation-maximization algorithm, and the individual inferred haplotype probabilities were compared between cases and controls using score test statistics under the dominant model. Only haplotypes with frequencies higher than 0.03 were analyzed for their associations. The test associations were determined from P-values. ORs and 95% CIs were obtained using inferred counts of haplotypes as input into the STATA package. Only the haplotypes with global P-values less than 0.05 were presented. When P-values were not subscripted, all P-values were empirical, twotailed values, and a value less than 0.05 was considered statistically significant.
Results
Characteristics of the study population
Of the patients identified, only 43 affected patients met the inclusion criteria and were enrolled in the study. These patients included 36 (83.72%) SJS and seven (16.28%) TEN patients. Ninety-one patients who had used co-trimoxazole for more than 6 months without evidence of any cutaneous reaction were recruited as controls. Demographic data of co-trimoxazole-induced SJS and TEN patients and co-trimoxazole-tolerant patients are summarized in Table 1 . Apart from the age of the patients, there were no significant differences in sex, indications for co-trimoxazole, and comorbidities between the case and the control groups.
Among the 43 patients in the co-trimoxazole-induced SJS/TEN group, indications of co-trimoxazole use were clearly specified in the medical records of only 38 patients. Of these patients, 30 (78.95%) had been diagnosed with HIV/AIDs, 29 of whom had received cotrimoxazole as the medication for prevention of PJP and one had received this medicine for PJP treatment. The rest of the patients in the case group (8/38, 21.05%) had been prescribed co-trimoxazole for the treatment of other diseases such as urinary tract and respiratory tract infections, diarrhea, acne, or sepsis (Table 1) .
Patients in the SJS/TEN group were mostly middle aged, with a mean age of 37.28 11.89 years. The mean exposure time to co-trimoxazole until the first signs of SJS/TEN appeared (onset) was 20.14 20.33 days, with a median of 14 days (range from 1 to 75 days; Table 1 ). The mean time of onset of SJS/TEN in HIV-positive patients (24.93 21.38 days) was about 2.5 times longer than that in HIV-negative patients (8.88 14.64 days, range from 1-35 days). The median time of onset of SJS/TEN in HIV-positive patients was 16 days (range 2-75 days) and in HIV-negative patients was 3 days (range 1-35 days; data not shown).
All of the patients in the co-trimoxazole-induced SJS/TEN group were admitted to the hospital for treatment of SCARs, and the median length for hospital stay was 8 days (range from 2 to 51 days; Table 1 ). The length of hospital stay for co-trimoxazole-induced TEN patients was longer than that for co-trimoxazole-induced SJS patients. The median length of hospital stay was 13 days for the TEN group, ranging from 9 to 51 days, with a mean SD of 22.20 17.37 days, compared with 7 days (2-46 days) for the SJS group, with a mean SD of 9.00 8.72 days (data not shown).
Apart from skin lesions, mucosal involvement including the eye, the oral mucosa, and the genitalia, as well as systemic manifestations including hepatitis, pneumonia, and renal insufficiency were also observed in the SJS/TEN group (Table 2 ). There were no apparent differences in concomitant medications between the case and control groups. The common concomitant medications used by both groups were doxycycline, efavirenz, ethambutol, fluconazole, isoniazid, lamivudine, nevirapine, paracetamol, rifampicin, stavudine, and zidovudine. Naranjo and ALDEN algorithms were used for assessment of these concomitant drugs, and none of them were likely to have been associated with SCARs in the study population.
Associations between HLA alleles and co-trimoxazoleinduced SJS/TEN Four loci of HLAs including HLA-A, HLA-B, HLA-C, and HLA-DRB1 were genotyped in individual patients. A comparison of HLA allele frequencies found in the SJS/TEN patients and the co-trimoxazole-tolerant controls is shown in the Supplementary Tables 1-4, Supplemental digital content 1 (http://links.lww.com/FPC/ A857). Only the alleles and haplotypes of HLA that showed a significant association when compared with the tolerant controls are presented in Table 3 .
HLA genotyping data of the SJS/TEN patients and the tolerant control patients revealed that the frequencies of three HLA alleles including HLA-B*15:02, HLA-C*06:02, and HLA-C*08:01 were statistically significantly higher in the co-trimoxazole-induced SJS/TEN group compared with the control group (Table 3) . On comparing these three alleles, HLA-C*06:02 had the highest OR, followed by HLA-B*15:02 and HLA-C*08:01. The HLA-C*06:02 allele was present in 5/43 (11.63%) co-trimoxazole-induced SJS/TEN patients, compared with 1/91 (1.10%) tolerant controls. The risk for co-trimoxazole-induced SJS/TEN was significantly higher among patients with HLA-C*06:02 when compared with those who did not carry this allele, with an OR of 11.84 (95% CI, 1.24-566.04; P = 0.0131). In addition, the frequency of the HLA-B*15:02 genotype was significantly higher in the SJS/TEN group compared with the tolerant control group [14/43 (32.56%) versus 10/91 (10.99%)], and the risk for SJS/TEN among the patients with this allele was 3.91 (95% CI, 1.42-10.92; P = 0.0037). Similarly, the frequency of the HLA-C*08:01 genotype was significantly higher in the SJS/TEN group compared with the tolerant control group, with an OR of 3.53 (95% CI, 1.21-10.40; P = 0.0108; Table 3 ). The frequencies and ORs of these HLA alleles were compared with those previously reported in the general northeastern Thai population (Table 3 ) [20] . Only the HLA-B*15:02 (OR = 2.40, 95% CI = 1.11-4.98; P = 0.0202) allele was found to be associated with these reactions on comparing the HLA allele frequencies in SJS/TEN patients with those reported in the general Thai population.
Results from haplotype analysis revealed that only the frequencies of the HLA-B*15:02-C*08:01 and HLA-B*15:02-C*08:01-DRB1*12:02 haplotypes in the cotrimoxazole-induced SJS/TEN group were statistically significantly different from those in the tolerant control group. The OR of co-trimoxazole-induced SJS/TEN among patients with the HLA-B*15:02-C*08:01 haplotype was 4.87 (95% CI, 1.48-17.22; P = 0.0041), whereas the OR among those with the HLA-B*15:02-C*08:01-DRB1*12:02 haplotype was 4.97 (95% CI, 1.22-23.72; P = 0.0185; Table 3 ).
On subgroup analyses of HIV/AIDs patients (30 and 61 patients in the case and tolerant control groups, respectively), only two HLA alleles, HLA-B*15:02 and HLA-C*08:01, were found to be significantly different between the case and control groups. The highest OR (11.19, 95% CI = 2.52-66.83; P = 0.0002; P c = 0.0122) was observed among patients with HLA-C*08:01, followed by those with HLA-B*15:02 (OR = 6.11, 95% CI = 1.77-22.42; P = 0.0015; Table 3 ).
Haplotype analysis in the HIV/AIDS subgroup revealed that the risk for co-trimoxazole-induced SJS/TEN was significantly higher among patients with the HLA-A*11:01-B*15:02-C*08:01, HLA-B*15:02-C*08:01, HLA-B*15:02-C*08:01-DRB1*12:02, and HLA-A*11:01-B* 15:02-C*08:01-DRB1*12:02 haplotypes, with OR values of more than 7 (range 7.38-18.26, P = 0.01-001; Table 3 ).
Discussion
In this study, HLA class I and II genotypes were determined in 43 patients with co-trimoxazole-induced SJS/TEN and 91 patients who were tolerant to cotrimoxazole. Of the HLA alleles determined, only three HLA alleles including HLA-B*15:02, HLA-C*06:02, and HLA-C*08:01 were significantly higher in the Table 2 Summary of clinical characteristics of co-trimoxazole-induced SJS/TEN patients (400/80), sulfamethoxazole 400 mg and trimethoprim 80 mg; bid, twice daily; DM, diabetes mellitus; F, female; HT, hypertension; M, male; NA, not available; od, daily; SCARs, severe cutaneous adverse reactions; SJS, Stevens-Johnson syndrome; SLE, systemic lupus erythematosus; tab, tablets; TB, tuberculosis; TEN, toxic epidermal necrolysis; tid, three times daily. Table 3 List of the alleles and haplotypes of HLA that showed the highest OR values for SJS/TEN induced by co-trimoxazole in the study population The bold values in Table 3 co-trimoxazole-induced SJS/TEN group compared with the control group. The HLA-B*15:02-C*08:01 and HLA-B*15: 02-C*08:01-DRB1*12:02 haplotypes were significantly associated with co-trimoxazole-induced SJS/TEN, particularly among HIV-positive patients. Unlike a markedly strong association between carbamazepine-induced SJS/TEN and the HLA-B*15:02 allele or allopurinol-induced SCARs and the HLA-B*58:01 allele reported in the Thai population, only weak associations between these HLA alleles and cotrimoxazole-induced SJS/TEN were observed in the study population. Because of the fact that the incidence of SCARs is very rare, a small sample size is a limitation of many of previous studies, as well as the present study. To the best of the authors' knowledge, however, this study is the largest case-control study of HLA genetic polymorphisms and cotrimoxazole-induced SCARs. Results from the genetic power calculation demonstrated that by using the number of cases and controls enrolled in the present study and assuming allele frequencies of more than 10%, LD of more than 0.8, and an OR of more than 4, the association between HLA alleles could be detected at 80% power at a 0.05 type I error rate.
Among the 43 SJS/TEN patients enrolled in the present study, 30 were HIV-positive patients. Consistent with previous studies [3, 21] , the incidence of SJS and TEN seems to be more common among HIV-positive patients than in the general Thai population. It should be noted, however, that the higher frequency of HIV-positive patients in the case group may be because of the fact that the use of co-trimoxazole for the treatment of infections other than PJP, which is a common opportunistic infection in HIV/AIDs patients, is restricted because of awareness of its severe cutaneous adverse drug reactions.
It is now well recognized that HLA molecules are key elements of severe cutaneous reactions caused by several drugs. To date, at least three hypotheses including hapten/prohapten, pharmacological interaction of drugs with immune receptors, and alteration of the MHCpresented self-peptide repertoire have been proposed to explain how HLA molecules and T-cell receptors (TCRs) interact with drugs and peptides, leading to an immune response of SCARs [22] . The most striking evidence for the role of specific HLA molecules in druginduced SCARs is the association between HLA-B*57:01 and abacavir-induced hypersensitivity [13] , HLA-B*15:02 and carbamazepine-induced SJS/TEN [4, 6, 10, 23] , and HLA-B*58:01 and allopurinol-induced SCARs [5, 9, 11] .
On comparing 43 SJS/TEN patients and 91 controls, the frequencies of HLA-B*15:02, HLA-C*06:02, and HLA-C*08:01 alleles were found to be significantly higher in co-trimoxazole-induced SJS/TEN patients compared with controls. The risks for co-trimoxazole-induced SJS/TEN were higher among patients with allele HLA-C*06:02, with an OR of 11.84 (95% CI, 1.24-566.04; Table 3 ). The allele frequencies of these HLA alleles previously reported in a northeastern Thai population with similar ethnicity to the participants of the present study were apparently higher than those among co-trimoxazole-tolerant controls [20] . When the frequencies of HLA alleles in the SJS/TEN group were compared with those in the general northeastern Thai population, only the HLA-B*15:02 allele was found to be associated with co-trimoxazole-induced SJS/TEN (OR = 2.40, 95% CI = 1.11-4.98; P = 0.0202), whereas the HLA-C*08:01 allele was apparently associated with co-trimoxazole-induced SJS/TEN (OR = 2.07, 95% CI = 0.92-4.41; P = 0.0536). [6, 24] .
Several haplotypes of HLA, particularly the HLA-B* 15:02-C*08:01 and HLA-B*15:02-C*08:01-DRB1*12:02 haplotypes, were higher in SJS/TEN patients compared with co-trimoxazole-tolerant controls. Increased risks for co-trimoxazole-induced SJS/TEN in patients with these haplotypes were observed. Moreover, the frequency of HLA-B*15:02-C*08:01 haplotype carriers among SJS/TEN patients was significantly higher than previously reported in a general northeastern Thai population (6.75%).
Compared with the data obtained from the general northeastern Thai population, patients who carried the HLA-B*15:02-C*08:01 haplotype showed an approximately four-to six-fold increased risk for SJS/TEN caused by cotrimoxazole.
When the P-values were adjusted for multiple comparisons using Bonferroni's correction (12 for HLA-A, 20 for HLA-B, 16 for HLA-C, and 13 for HLA-DRB1), none of these associations, except that of the HLA-C*08:01 allele in the HIV-positive group, were considered statistically significant. The OR in HIV-positive patients who carried the HLA-C*08:01 allele was 11.19 (95% CI, 2.52-66.83; P = 0.0002; P c = 0.0122). This finding suggests that the HLA-C*08:01 allele may be a valid marker for SJS/TEN associated with co-trimoxazole, particularly in HIVpositive patients.
Previous studies on HLA-B Co-trimoxazole is a combination of sulfamethoxazole and trimethroprim; however, sulfamethoxazole is thought to be responsible for most of the hypersensitivity. Sulfamethoxazole undergoes extensive metabolism in vivo through several drugmetabolizing enzymes including cytochrome P450 2C9, glutathione-S-transferases (GST), and N-acetyltransferases [25] . About 2% of an oral dose of sulfamethoxazole is excreted as the hydroxylamine in human urine, and this metabolite subsequently undergoes rapid autoxidation to nitroso sulfamethoxazole, which is chemically reactive. Nitroso sulfamethoxazole has been shown to haptenate cellular proteins, including the surface of viable lymphocytes and keratinocytes [26] [27] [28] , and this reactive metabolite can be detoxified by glutathione [29] . Genetic polymorphisms of drug-metabolizing enzymes involved in the activation and detoxification of sulfamethoxazole may theoretically be associated with the risk for SCARs associated with this drug; however, the findings are quite discrepant. It has been reported in HIV-negative and HIV-positive patients that the slow acetylator phenotype is a risk factor of sulfamethoxazole hypersensitivity [30, 31] . In addition, a higher frequency of the GSTM1 null genotype was observed in HIV-positive patients with sulfamethoxazole hypersensitivity than in sulfamethoxazole-tolerant patients or in HIV-negative patients [32] . In contrast, HIV-negative patients showed no significant association between GSTM1 activity and sulfamethoxazole hypersensitivity [33] . A previous study in HIV-positive patients was also unable to demonstrate an association of sulfamethoxazole hypersensitivity with genetic polymorphisms of cytochrome P450 2C9, GST, and N-acetyltransferase 2 enzymes [34] . In addition, a genetic polymorphism in the catalytic subunit of glutamate cysteine ligase, which is a ratelimiting enzyme in the biosynthesis of glutathione, has recently been reported to be associated with sulfamethoxazole-induced hypersensitivity in HIV/AIDS patients [29] .
Furthermore, recent data from molecular dynamic simulations of a TCR containing variable domain Vβ20-1, sequenced from sulfamethoxazole-responsive T cells, reveal that sulfamethoxazole clearly causes a change in the TCR conformation and the peptide-HLA affinity, indicating that TCRs containing Vβ20-1 have a role in cutaneous adverse drug reactions caused by this drug [35] . It is possible that variations in the TCR may play a role in the risk for sulfamethoxazole hypersensitivity.
Moreover, CD8 + T lymphocytes exhibiting drug-specific cytotoxicity were found in the blister fluid of patients with co-trimoxazole-related TEN, and these specific cytotoxic lymphocytes were restricted by HLA class I, particularly HLA-Cw4, and used the perforin/granzymemediated pathway to exert their killing effect [36, 37] . Furthermore, a previous study in 28 sulfamethoxazolerelated SJS/TEN patients of European ancestry reported that the HLA-B*38:01 and HLA-B*38:02 alleles were statistically significantly associated with SJS/TEN caused by sulfamethoxazole, with ORs of 4.3 (95% CI, 1.4-12.7; P = 0.022) and 76 (95% CI, 4.6-1250; P = 0.027), respectively [7] . The HLA-B*38:02 allele was the only allele in the HLA-B*38 group that was found in the present study population, and this allele was present in only 2/43 (4.65%) co-trimoxazole-induced SJS/TEN patients and 10/91 (10.99%) co-trimoxazole-tolerant controls. The risk for co-trimoxazole-induced SJS/TEN in the patients who carried the HLA-B*38:02 allele was not statistically significant in this study population (OR = 0.40, 95% CI, 0.04-1.99; P =0.3336; Supplementary Table 2, Supplemental digital content 1, http://links.lww.com/FPC/ A857). In addition, weak associations between the HLA-A*29, HLA-B*12, and HLA-DR*7 alleles and sulfonamide-related TEN were reported in 13 French patients [1] . Because of the unavailability of a highresolution HLA genotyping technique, the definite alleles of HLA could not be reported in the French study. None of these HLA alleles, however, were associated with SJS/TEN in the current study population (Supplementary Tables 1-4 , Supplemental digital content 1, http://links.lww.com/FPC/A857).
Ethnic differences in the association between HLA-B*15:02 and carbamazepine-induced SJS/TEN are well recognized. An extraordinarily strong association between HLA-B*15:02 and carbamazepine-induced SJS/TEN was observed only in Han Chinese and Southeast Asian populations, but not in White and Japanese populations [38] . Moreover, it has been shown in Japanese and Korean patients that HLA-B*15:11 was a risk factor for carbamazepine-induced SJS/TEN [39, 40] . In addition, evidence from genomewide association studies has revealed that HLA-A*31:01 appears to be a good genetic marker of carbamazepine-induced cutaneous adverse reactions in Japanese and White populations [41, 42] . Whether HLA-B*15:02, HLA-C*06:02, and HLA-C*08:01 alleles are associated with co-trimoxazole-induced SJS/TEN in other southeast Asian populations needs to be explored.
